tbuckley/cabot-search huggingface dataset:
Is there a need of "catch-up' polio vaccination in preadolescence?
Authors: S. G. Wassilak
Journal: JAMA (1981)

The introduction and widespread use of the inactivated and live poliovirus vaccines in the United States have brought about a dramatic reduction in the incidence of poliomyelitis: More than 20,000 paralytic cases were reported in 1952, whereas the current annual average is less than 20.<sup>1,2</sup>As a consequence of this extraordinary degree of control, there is virtually no wild poliovirus circulation in the United States; individual protection from wild virus introduction depends on successful vaccination. Data available in 1976 and 1977 indicated that a substantial proportion (perhaps one third) of American children younger than 5 years had not received a full course of trivalent oral polio vaccine (TOPV).<sup>3,4</sup>These and other findings led a study group convened by the Institute of Medicine, National Academy of Sciences, to recommend routine administration of an additional dose of TOPV at age 11 to 12 years.<sup>5</sup>This dose was proposed not
GENEVA
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Heart/lung recipient becomes first living heart donor in United States
Authors: B. Merz
Journal: JAMA (1987)

"TAKE MY HEART!" Although millions of men in the United States may have uttered this phrase, only one has meant it literally. He is Clinton House, a 28-year-old patient with cystic fibrosis, who, in receiving a heart/lung graft from an accident victim, became cardiac donor to 38-year-old John Couch, a patient with ischemic cardiomyopathy. The procedures, which were performed by surgical teams at Johns Hopkins Medical Center in Baltimore under the direction of William A. Baumgartner, MD, and Bruce Reitz, MD, marked the first time in the United States that a heart transplant recipient's own heart was recycled. A public information officer at Harefield Hospital near London reported that surgeons at that hospital had performed two similar operations in April and early May. Baumgartner, who is director of heart/lung transplantation at the US center, and Reitz, who is director of cardiovascular surgery, were among those who pioneered heart/lung transplantation at
Metastasis to the site of recent trauma
Authors: B. Benisch
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE JOURNAL SPECIAL TRAIN TO DENVER.
Journal: JAMA (1898)

The Journal Special Trainwill leave the Union Depot, Adams and Canal Streets, Chicago, Saturday, June 4, at 11 P.M., via the Chicago, Burlington &amp; Quincy Railroad, arriving in Denver Monday morning 7 A.M., in time for the meeting of the American Academy of Medicine, the American Medical Editors' Association and other medical organizations holding sessions on Monday. Pay no attention to statements other than those announced in theJournal. The reason for arranging for the stop-over on the return trip was owing to the fact that the Exposition at Omaha will be in much better condition then than now. Passengers from the East taking theJournal Specialat Chicago may have their stop-over arranged without extra cost. The " Special " will run through. Tickets will be good for thirty days. The rate will be one fare and $2 for the round trip, the most favorable rate yet granted theAssociation
Reply
Authors: Young‐Sun Lee, Myung Han Hyun, Sun Young Yim, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun
Journal: Hepatology (2018)

Potential conflict of interest: Nothing to report. We thank Labgaa et al. for their interest in our recent meta‐analysis comparing hepatic resection and transarterial chemoembolization (TACE) in intermediate‐ to advanced‐stage hepatocellular carcinoma (HCC).1 We comment on two issues that they pointed out. The first issue is the inclusion of patients with sequential treatment after TACE, such as surgery and local ablation in one study (by Luo et al.). In clinical practice, sequential treatment after primary treatment, including surgical resection, is common, and sometimes it is inevitable to improve the prognosis of patients with HCC. Moreover, although there was no comment on sequential treatment after primary therapy in other enrolled studies, it could be easily inferred that the patients in enrolled studies might have received other sequential treatment in clinical practice. Therefore, there is no need to exclude this study in our meta‐analysis. The second issue is whether it is appropriate to include patients with solitary HCC more than 5 cm as Barcelona Clinic Liver Cancer (BCLC) stage B. Because BCLC classifies a single large HCC more than 5 cm as BCLC A and recommends surgical resection as the first treatment option,2 we fully agreed with the opinion of Labgaa et al. However, since the development of BCLC systems, there had been ongoing debate as to whether a single HCC >5 cm is BCLA A or B.3 Most studies enrolled in our meta‐analysis were performed in the midst of controversy, and seven of nine studies classified solitary HCC more than 5 cm as BCLC B. Principally, meta‐analysis should follow the original data faithfully. Moreover, most clinicians do not determine the treatment according to the BCLC stage alone; treatment is not changed depending on whether a single large mass more than 5 cm belongs to BCLC A or B.5 Therefore, our meta‐analysis reflects the real clinical practice and research limit, and it could not be an essential problem to reanalysis. We carefully rereviewed seven studies again, and there were no further detailed data with which to analyze survival in patients with BCLC B excluding a single large mass >5 cm. As patients with BCLC B HCC are considered heterogeneous, determining optimal treatment modality is an important issue. Despite some misunderstanding regarding BCLC B criteria in enrolled studies of our meta‐analysis, our study suggested hepatic resection could have survival benefits in patients with intermediate to advanced stage HCC.
Prognostic Value of Kras Mutations in Stage III Colon Cancer: Post-Hoc Analyses of the Petacc8 Phase III Trial
Authors: H. Blons, J. Emile, K. Le Malicot, A. Zaanan, J. Tabernero, E. Mini, G. Folprecht, J. van Laethem, J. Thaler, J.A. Bridgewater, L. Petersen, E. Van Cutsem, C. Lepage, R. Salazar, P. Laurent-Puig, J. Taieb
Journal: Annals of Oncology (2014)
Muscular dystrophy, alveolar hypoventilation, and papilledema
Authors: W. M. McCormack
Journal: JAMA (1966)

The importance of chronic respiratory disorders with hypercapnia in the differential diagnosis of papilledema was seen in a patient with progressive muscular dystrophy which resulted in alveolar hypoventilation, hypercapnia, and severe retinopathy including papilledema. Improved ventilation resulted in the return of the bloodgas levels toward normal and resolution of the retinopathy. Postmortem examination revealed a normal central nervous system. The papilledema could be ascribed to the respiratory insufficiency with carbon-dioxide retention.
Enlarged Angiography by Venous Passage
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A patient with suspected miscarriage is found to have hypertension, renal failure, and thrombocytopenia: case progression
Authors: Chris M Laing, Rhys Roberts, Liz Lightstone, Alison Graham, Terry H Cook, Shaun Summers, Charles D Pusey
Journal: BMJ (2007)

This is the second of a three part case report where we invite readers to take part in considering the diagnosis and management of a real patient using rapid response on bmj.com.In three weeks' time we will report the outcome and summarise the responses.We welcome contributions of interactive case reports.Cases should raise interesting clinical, investigative, diagnostic, and management issues but not be so rare that they appeal to only a minority of readers.
O10.02 * MITOTIC INDEX, MICROVASCULAR PROLIFERATION AND NECROSIS DEFINE THREE GROUPS OF 1P/19Q CO-DELETED ANAPLASTIC OLIGODENDROGLIOMAS ASSOCIATED WITH DIFFERENT GENOMIC ALTERATIONS
Authors: D. Figarella-Branger, K. Mokhtari, C. Dehais, A. Jouvet, E. Uro-Coste, C. Colin, C. Carpentier, F. Ducray, A. Idbaih, F. P. Network
Journal: Neuro-Oncology (2014)

BACKGROUND: The aim of this study was to correlate histological features and molecular characteristics in anaplastic oligodendrogliomas (AO). METHODS: The histological characteristics of 203 AO patients enrolled in the French national network POLA were analyzed. The genomic profiles of 191 cases were studied using genomic arrays. IDH mutational status was assessed by immunohistochemistry and direct sequencing. RESULTS: 1p/19q co-deletion was present in 79% of cases and was associated with alpha-internexin expression (p < 10-4), IDH1/2 mutation (p < 10-4), chromosome 4 loss (p < 10-3), and better overall survival (p < 10-4). Based on mitotic index, microvascular proliferation (MVP) and necrosis, 3 groups of 1p/19q co-deleted AO were identified: AO with more than 5 mitoses per 10-HPF, no MVP and no necrosis, (1), AO with MVP and no necrosis (2) and AO with MVP and necrosis (3). Compared to group 1, group 2 and 3 AO had a higher mean Ki-67 proliferation index and a higher rate of 9p and 9q losses. Compared to group 2, group 3 AO had a higher number of chromosomal alterations including chromosome 4 loss. In the subgroup of 157 1p/19q co-deleted AO, chromosomal instability was associated with shorter progression free survival (p = 0.024) and shorter overall survival (p = 0.023). CONCLUSIONS: The present study shows that oligodendroglioma with classic histological features remains a molecularly heterogeneous entity and should be stratified according to 1p/19q status because of its major prognostic relevance. Moreover, 1p/19q co-deleted AO are also heterogeneous. Interestingly, mitotic index, MVP and necrosis help to classify them into three groups associated with distinct genomic alterations.
Personalized messages invite more mammography
Authors: R. Voelker
Journal: JAMA (1994)

TAILORED LETTERS and telephone calls may emerge as effective new weapons in the stepped-up fight against breast cancer. The tactics can't come quickly enough. New national figures show that more women past age 40 have received mammograms in recent years, but most still are not routinely screened. Conflicting guidelines don't help. Many physicians now question what constitutes "routine" screening, so experts say it's increasingly important to discuss mammography, along with breast self-examination, with patients. And even though family physicians may be trying to prompt more women to have mammograms, experts attribute low screening rates to high-risk patients being cared for by specialists who overlook the need for mammography. <h3>Patterns in Mammography</h3> From 1987 to 1990, the number of women older than age 40 who received a mammogram in the past year nearly doubled, from 17% to 33%, according to figures compiled by the National Center for Health Statistics, Hyattsville, Md.
Medizinische Praxis: Sammlung für ärztliche Fortbildung
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Increased gene expression of water channel in cirrhotic rat kidneys
Authors: Y ASAHINA
Journal: Hepatology (1995)

In patients with liver cirrhosis, impaired water and sodium excretion has been incriminated in the pathogenesis of ascites formation. Increased reabsorption of water in the distal nephron has been shown to play an important role in water retention in cirrhotic rat kidneys. Recently, a complementary DNA (cDNA) for the vasopressin-regulated water channel (the aquaporin of the apical membrane of the kidney collecting duct [AQP-CD]) has been cloned. It is suggested that AQP-CD plays an important role in renal water handling. Therefore, in the present study, to investigate the pathogenic role of the water channel in water retention in liver cirrhosis, gene expression of AQP-CD in the kidney was evaluated in cirrhotic rats. Liver cirrhosis was induced by an intraperitoneal administration of carbon tetrachloride twice a week for 12 weeks in 14 rats. Messenger RNA expression of AQP-CD in whole kidney homogenates determined by northern blot hybridization was significantly increased in cirrhotic rats (147%; P<.01) and dehydrated rats (206%; P<.0001) compared with control rats. Protein expression of AQP-CD in the homogenates of kidney medulla determined by Western blot analysis was significantly increased in cirrhotic rats (203%; P<.03) compared with control rats. Furthermore, mRNA expression of AQP-CD in the kidney showed a significant correlation with the volume of ascites in cirrhotic rats (r = 0.62, P<.02). No significant difference was observed in water intake, urinary volume, serum osmolality, serum sodium, and creatinine clearance between control and cirrhotic rats, suggesting that dehydration was unlikely in cirrhotic rats. From these results, it is concluded that renal mRNA expression of AQP-CD plays an important role in abnormal water retention followed by the development of ascites in liver cirrhosis. (Hepatology 1995;21:169–173).
Association of high symptom burden with oral oncolytic agents.
Authors: Jane Alcyne Severson, Emily R. Mackler, Bernard Marini, Douglas W. Blayney
Journal: Journal of Clinical Oncology (2015)

9613 Background: Increasing numbers of cancer patients are being treated with oral oncolytics. This change represents a shift from frequent direct observation during intravenous therapy to periodic observation and self-management. Despite this shift, patients are still at risk for many of the same chemotherapy-associated symptoms and toxicities. We sought to characterize the symptom burden experienced by patients prescribed oral oncolytics. Methods: Michigan Oncology Quality Consortium (MOQC) sponsored a collaborative focused on improving oral oncolytic care. Eight oncology practices participated. Patient symptoms were assessed with a modified Edmonton Symptom Assessment System (ESAS) prior to each outpatient visit. 13 symptoms were categorized as mild (0 to 3), moderate (4 to 6), and severe (7 to 10). A total of 1196 surveys were analyzed. Results: Overall, the average ESAS symptom score was mild in 83% of patients, moderate in 12% of patients, and severe in 5% of patients. These composite scores, however, obscure the significant symptom burden in select ESAS domains. For example, 34% of patients categorized their overall well-being as being moderate/severely affected; 35% of patients felt they were moderate/severely fatigued, and 20% indicated moderate/severe pain symptoms. Notably, 271/1196 (23%) of the assessments had 4 or more symptoms reported moderate to severe. (See table). Conclusions: Whether due to underlying disease or medication side effects, patients taking oral oncolytics experience significant symptom burden that impacts quality of life. Intolerance of oral oncolytics may lead to adherence issues, potentially affecting expected outcomes. Given the prevalence of symptoms and potential for toxicity, self-management strategies to improve early recognition and treatment of symptoms by patients taking oral oncolytics are necessary. Oral oncolytic symptom burden profile. Mild (0-3) Moderate (4-6) Severe (7-10) Pain 80% 15% 5% Tiredness 65% 21% 14% Drowsiness 76% 16% 8% Nausea 92% 6% 2% Appetite 79% 13% 8% Shortness of Breath 88% 9% 3% Depression 87% 11% 2% Anxiety 87% 10% 3% Well Being 66% 21% 13% Constipation 88% 9% 3% Diarrhea 92% 5% 3% Tingling/ Numbness 82% 12% 6% Mouth Sores 96% 3% 1% Overall Symptom Burden (n = 1196) 83% 12% 5%
Blocking IRE1a-endoribonuclease activity in hepatic stellate cells decreases tumor cell proliferation and metastasis in hepatocellular carcinoma
Authors: Natasa Pavlovic, Kessarin Thanapirom, Giuseppe Mazza, Krista Rombouts, Pär Gerwins, Femke Heindryckx
Journal: Journal of Hepatology (2020)
Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histocompatibility complex class II and BB1/B7 expression*1
Authors: K TSUNEYAMA
Journal: Hepatology (1995)

Primary biliary cirrhosis (PBC) is a chronic autoimmune liver disease characterized histologically by nonsuppurative destructive cholangitis. Sera from patients with PBC react with a series of intramitochondrial enzymes with the immunodominant response directed against the E2 component of the pyruvate dehydrogenase complex (PDC-E2). Recently, using tissue sections of late-stage PBC, we showed that there is increased expression in biliary epithelial cells of patients with PDCE2 or a molecule cross-reactive with PDC-E2. Previous work has shown that biliary epithelial cells of patients with PBC express an increased amount of class II. To address the sequence of events in the evolution of PBC, we have focused our attention in this study on early biliary epithelial lesions. In particular, we have studied the liver of 22 female patients with PBC that was diagnosed as either stage I or stage II using both a mouse monoclonal antibody that has reactivity similar to human autoantibodies as well as a human Fab combinatorial prepared from the lymph node of a PBC patient. Tissues were simultaneously stained using antibodies to PDC-E2, class II, and BB1/B7. As a positive control, tissues from late-stage PBC were studied concurrently. By determining the order of expression among the three molecules, PDC-E2, class II, and BB1/B7, we report that the expression of PDC-E2 or a PDC-E2-like molecule on biliary duct epithelium of patients with PBC precedes the expression of BB1/B7 and major histocompatibility complex (MHC) class II molecules. The alteration of an autoantigen in biliary duct epithelial may be the earliest lesion in PBC.
Snakebite Revisited
Authors: John C. Key
Journal: JAMA (1981)

<h3>To the Editor.—</h3> The physician's dilemma was precisely stated by Robert K. Myles, MD (1981;245:1579). Recent literature<sup>1</sup>(1976;235:2513, 1978; 240:654) on snakebite management is controversial and contradictory. Each school of thought reports its results in an inadequate, almost anecdotal fashion, ignoring both the work of others and its own shortcomings. Administration of antivenin is not innocuous; the incidence of serum sickness approaches 100%, regardless of the volume used. Early debridement, fasciotomy, and bite excision may produce large wounds, delayed healing, and increased morbidity. Is there nothing in between? Our experience in treating 42 cases of Crotalidae envenomation has indicated that the treatment of snakebite, like that of other diseases, must be individualized. No single method is adequate; often a combination of techniques must be used.